|Full Name||ectodermal-neural cortex 1 (with BTB-like domain)|
|Product Description||Rabbit polyclonal antibody to ENC1 (ectodermal-neural cortex (with BTB-like domain))|
|Background||DNA damage and/or hyperproliferative signals activate wildtype p53 tumor suppressor protein (TP53; MIM 191170), inducing cell cycle arrest or apoptosis. Mutations that inactivate p53 occur in 50% of all tumors. Polyak et al. (1997) [PubMed 9305847] used serial analysis of gene expression (SAGE) to evaluate cellular mRNA levels in a colorectal cancer cell line transfected with p53. Of 7,202 transcripts identified, only 14 were expressed at levels more than 10-fold higher in p53-expressing cells than in control cells. Polyak et al. (1997) [PubMed 9305847] termed these genes 'p53-induced genes,' or PIGs, several of which were predicted to encode redox-controlling proteins. They noted that reactive oxygen species (ROS) are potent inducers of apoptosis. Flow cytometric analysis showed that p53 expression induces ROS production, which increases as apoptosis progresses under some conditions. The authors stated that the PIG10 gene, also called ENC1, encodes an actin-binding protein.[supplied by OMIM]|
|Synonyms||CCL28 antibody, ENC-1 antibody, FLJ39259 antibody, KLHL35 antibody, KLHL37 antibody, NRPB antibody, PIG10 antibody, TP53I10 antibody, ENC1 antibody, "nuclear restricted protein, BTB domain-like (brain) antibody", nuclear matrix protein NRP/B antibody, kelch-like protein 37 antibody, kelch-like 37 antibody, ectoderm-neural cortex protein 1 antibody, ectodermal-neural cortex (with BTB-like domain) antibody, p53-induced gene 10 protein antibody, tumor protein p53 inducible protein 10 antibody, kelch-like 35 antibody, ectodermal-neural cortex 1 (with BTB-like domain) antibody|
|Cellular Localization||Nucleus matrix , Cytoplasm , cytoskeleton |
|Immunogen||Recombinant protein encompassing a sequence within the center region of human ENC1. The exact sequence is proprietary.|
|Predicted Cross Reactivity species Predicted cross-reactivity:|
Predicted cross-reactivity is based on sequence homology, with greater than 80% immunogen sequence identity considered positive.
Please note that we are only able to guarantee products to work in applications and species in which they have been tested.
|Human, Mouse, Rat, Rhesus Monkey, Bovine|
|Predict Reactivity Note||Human (100%), Mouse (98%), Rat (98%), Rhesus Monkey (99%), Bovine (100%)|